We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Pay for delay

15 May 2006 By Robert Cyran

The UK drug maker is paying a fat 70% premium for Cambridge Antibody, partly because it was still bound by an existing standstill agreement. Biotech groups are in essence an option. The agreement effectively extended CAT’s maturity, which jacked up the price.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)